Medifast INC

Medifast announced second quarter 2026 results showing a 27.6% revenue decrease to $76.4 million and a net loss of $3.1 million, impacted by a significant drop in active coaches.

Medifast, Inc. announced the rebranding of its lifestyle brand OPTAVIA to Trilivy, a comprehensive metabolic health system, marking a significant corporate transformation.

Medifast, Inc. announced the resignation of its Chief Legal Officer & Corporate Secretary, Jason L. Groves, effective May 29, 2026, with a separation agreement in place.

Medifast, Inc. announced the appointment of Nicholas Johnson as CEO, effective June 1, 2026, succeeding Daniel Chard who will remain Chairman, and the stockholder approval of an amendment to the 2012 Share Incentive Plan.

Medifast announced its first quarter 2026 financial results, reporting a revenue of $76.0 million and a net loss of $2.1 million, or $0.19 per diluted share.

Medifast and Steamboat Capital Partners LLC have entered a Cooperation Agreement, leading to new independent director nominations and a CEO transition plan.

Medifast, Inc. announced a substantial decline in revenue and a widening net loss for the second quarter of 2026, primarily driven by a significant decrease in active coaches.

Medifast, Inc. reported a significant revenue decrease for the first quarter of 2026, primarily due to a decline in active earning coaches and the ongoing impact of GLP-1 medications.

Medifast reported a significant revenue decline and net loss in Q3 2025, driven by a substantial decrease in active earning OPTA VIA coaches and ongoing market challenges.

Medifast, Inc. reported a significant 37.4% revenue decrease in Q2 2025, driven by a sharp decline in active OPTA VIA coaches, despite returning to net income.

Medifast's Q1 2025 revenue declined significantly due to a decrease in active earning OPTA VIA coaches, reflecting challenges in customer acquisition amid the rising popularity of GLP-1 medications.

Medifast, Inc. experienced a substantial decrease in revenue and profitability in the third quarter of 2024, primarily due to a decline in active coaches and the impact of GLP-1 medications on the weight loss market.

Medifast navigates a challenging year with a focus on adapting to the evolving weight-loss market and integrating GLP-1 solutions.

Medifast, Inc. reports a decrease in revenue and earnings for 2023, while outlining a strategic shift towards medically supported weight loss and other growth initiatives.

Director Jeffrey Matthew Rose acquired 18,419 shares of Medifast, Inc. common stock through a director compensation plan.

Director Parsa Kiai acquired 19,317 shares of Medifast, Inc. common stock as part of his annual director compensation package.

Director Andrea B. Thomas acquired 11,680 restricted stock units as part of her annual director fee compensation.

Director Scott Schlackman acquired 11,680 restricted stock units as part of his annual director fee compensation.

Medifast, Inc. director Elizabeth A. Geary was granted 11,680 restricted stock units as part of the company's director compensation plan.

Director Xian Ming was granted 11,680 cash-settled restricted stock units as part of an annual incentive plan.

Medifast, Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Medifast is asking stockholders to approve an amendment to its 2012 Share Incentive Plan to increase the number of shares available for awards by 550,000.

Medifast, Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Medifast is asking stockholders to approve an amended share incentive plan to attract and retain key personnel as the company navigates a changing weight loss industry landscape.

Activist investor Steamboat Capital Partners, holding 6.0% of Medifast, Inc., has reached a cooperation agreement to nominate two designees to the board and pursue cost-efficiency.

Citadel Securities and affiliated entities have filed a Schedule 13G reporting a 6.5% beneficial ownership stake in Medifast, Inc.

Charles Schwab Investment Management has reported an increase in its beneficial ownership of MediFast Inc. common stock, now holding 5.74% of the class.

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have filed a Schedule 13G, reporting beneficial ownership of 773,710 shares of Medifast Inc. common stock, representing 6.96% of the class.

The Vanguard Group reports 0% beneficial ownership in Medifast Inc. following an internal realignment.

G1 Execution Services, Susquehanna Fundamental Investments, and Susquehanna Securities collectively reported a 1.4% beneficial ownership in Medifast, Inc. as of December 31, 2025.

Charles Schwab Investment Management Inc. has reported a 7.06% beneficial ownership stake in Medifast Inc. common stock as of December 31, 2025.